Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBITDA Margin (2020 - 2023)

Historic EBITDA Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 228.43%.

  • Candel Therapeutics' EBITDA Margin rose 259038300.0% to 228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was 1479.42%, marking a year-over-year increase of 265213800.0%. This contributed to the annual value of 1596.7% for FY2024, which is 1172800.0% down from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' EBITDA Margin is 228.43%, which was up 259038300.0% from 1324.51% recorded in Q3 2023.
  • Candel Therapeutics' EBITDA Margin's 5-year high stood at 5148.39% during Q4 2021, with a 5-year trough of 55096.77% in Q2 2021.
  • Moreover, its 4-year median value for EBITDA Margin was 15022.58% (2021), whereas its average is 18362.96%.
  • Data for Candel Therapeutics' EBITDA Margin shows a peak YoY increase of 391096800bps (in 2021) and a maximum YoY decrease of -468096800bps (in 2021) over the last 5 years.
  • Quarter analysis of 4 years shows Candel Therapeutics' EBITDA Margin stood at 33961.29% in 2020, then soared by 115bps to 5148.39% in 2021, then crashed by -608bps to 26132.26% in 2022, then surged by 99bps to 228.43% in 2023.
  • Its EBITDA Margin was 228.43% in Q4 2023, compared to 1324.51% in Q3 2023 and 1487.42% in Q2 2023.